Abstract
The relevance and efficacy of long-term estrogen therapy is well established, though some undesirable side effects and contraindications persist. Raloxifene, the first selective estrogen receptive modulator (SERM) tested in phase III trials, offers a choice alternative. It increases bone mineral density, lowers serum lipid concentrations and reduces vertebral fractures.
Publication types
-
Clinical Trial
-
English Abstract
-
Randomized Controlled Trial
MeSH terms
-
Aged
-
Bone Density
-
Female
-
Humans
-
Lipids / blood
-
Menopause*
-
Middle Aged
-
Osteoporosis, Postmenopausal / prevention & control*
-
Placebos
-
Raloxifene Hydrochloride / adverse effects
-
Raloxifene Hydrochloride / therapeutic use*
-
Selective Estrogen Receptor Modulators / adverse effects
-
Selective Estrogen Receptor Modulators / therapeutic use*
-
Spinal Fractures / prevention & control*
Substances
-
Lipids
-
Placebos
-
Selective Estrogen Receptor Modulators
-
Raloxifene Hydrochloride